NEI Research News

NEI support leading to gene therapy clinical trials for people with Leber congenital amaurosis (LCA) consisted of significant efforts by investigators in the intramural laboratories at the NEI.

Three young adults with an inherited form of blindness showed evidence of improved day and night vision following a specialized gene transfer procedure in a phase 1 clinical trial funded by the National Eye Institute (NEI), part of the NIH.

Scientists have found that laser therapy is equivalent to two different dosages of corticosteroid medications for treating vision loss from the blockage of small veins in the back of the eye, a condition known as branch retinal vein occlusion (BRVO).

Eye injections of corticosteroid medication may improve patients’ vision

Three young adults who received gene therapy for a blinding eye condition remained healthy and maintained previous visual gains one year later, according to an August online report in Human Gene Therapy.

Erik Weihenmayer has climbed mountains around the world - the highest peaks, in fact, on every continent. One afternoon a few years ago, however, a climbing wall in a local gym served as the setting of a most memorable journey.

A compact fiber-optic probe developed for the space program has now proven valuable for patients in the clinic as the first non-invasive early detection device for cataracts, the leading cause of vision loss worldwide.

Millions of light-sensitive cells called photoreceptors fill the delicate tissue in the eye known as the retina. These cells include rods that provide night vision and cones that detect color.

In advance of NEI director Dr. Paul A. Sieving’s recent trip to China, a poster at Tianjin Eye Hospital promoted one of his lectures.

The National Eye Institute (NEI), part of the National Institutes of Health (NIH), announces the release of more than 10 years of data collected during the Age-Related Eye Disease Study (AREDS).